Search

Your search keyword '"Christopher R Cogle"' showing total 287 results

Search Constraints

Start Over You searched for: Author "Christopher R Cogle" Remove constraint Author: "Christopher R Cogle"
287 results on '"Christopher R Cogle"'

Search Results

1. Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.

2. Virotherapy using myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells.

3. Building a precision oncology workforce by multidisciplinary and case-based learning

4. Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/AML Disease Registry

5. Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA

6. Home Modifications for Older Adults: A Systematic Review

8. Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial

9. Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care

10. Specialized Proresolving Mediators in Symptomatic Women With Coronary Microvascular Dysfunction (from the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD [WARRIOR] Trial)

11. Data from DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks

12. Data from Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation

13. Supplementary Methods, Tables S1-4, Figures S1-4 from Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation

14. Supplementary Data from DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks

15. Genome-wide CRISPR/Cas9 Screen Identifies Etoposide Response Modulators Associated with Outcomes in Pediatric AML

16. Comparative effectiveness of mobile health smoking cessation approaches among underserved patients in primary care: Study protocol for the PROMOTE-UP trial

17. Building a precision oncology workforce by multidisciplinary and case-based learning

18. Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

19. Finding incident cancer cases through outpatient oncology clinic claims data and integration into a state cancer registry

20. Real‐world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower‐risk myelodysplastic syndromes

21. Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect®MDS/AML Disease Registry

22. Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipients

23. Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

24. Medicaid’s Moment for Protecting and Promoting Women’s Health

25. DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks

26. A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

27. A Phase III, Randomized Clinical Trial Comparing a Neutropenic Vs Liberalized Diets in Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT) or Remission Induction Chemotherapy for Acute Leukemia/ Myelodysplastic Syndrome (MDS): Results of Interim Analysis

28. A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients

29. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis

30. Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial

31. Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics

32. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia

33. DNMT3A harboring leukemia-associated mutations directs sensitivity to DNA damage at replication forks

34. Implementation of Cancer Plans in the United States: A Review

35. HOTTIP Dependent R-Loop Formation Regulates CTCF Boundary Activity and TAD Integrity in Leukemia

36. Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms

37. Functional Dependency Analysis Identifies Potential Druggable Targets in Acute Myeloid Leukemia

38. Cancer in the Time of Coronavirus: A Call for Crisis Oncology Standards of Care

39. Identification of Unique mRNA and miRNA Expression Patterns in Bone Marrow Hematopoietic Stem and Progenitor Cells After Trauma in Older Adults

40. Clinical Application of Computational Methods in Precision Oncology: A Review

41. Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes

42. Finding incident cancer cases through outpatient oncology clinic claims data and integration into a state cancer registry

43. Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes

44. Impact of the COVID-19 Pandemic on Colorectal and Prostate Cancer Screening in a Large U.S. Health System

45. Oncolytic Virotherapy for Hematological Malignancies

46. Functional genomic landscape of acute myeloid leukaemia

47. Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation

48. CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia

49. Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study

50. Following the Breadcrumbs of Palliative Care Financial Sustainability to Big Data

Catalog

Books, media, physical & digital resources